Advertisement

Topics

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

08:00 EDT 5th August 2017 | BioPortfolio

Summary of "Chiral pharmaceuticals: A review on their environmental occurrence and fate processes."

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics, pharmacodynamics and toxicity. The advancement in separation and detection methods has made it possible to analyze trace amounts of chiral compounds in environmental media. As a result, interest on chiral analysis and evaluation of stereoselectivity in environmental occurrence, phase distribution and degradation of chiral pharmaceuticals has grown substantially in recent years. Here we review recent studies on the analysis, occurrence, and fate of chiral pharmaceuticals in engineered and natural environments. Monitoring studies have shown ubiquitous presence of chiral pharmaceuticals in wastewater, surface waters, sediments, and sludge, particularly β-receptor antagonists, analgesics, antifungals, and antidepressants. Selective sorption and microbial degradation have been demonstrated to result in enrichment of one enantiomer over the other. The changes in enantiomer composition may also be caused by biologically catalyzed chiral inversion. However, accurate evaluation of chiral pharmaceuticals as trace environmental pollutants is often hampered by the lack of identification of the stereoconfiguration of enantiomers. Furthermore, a systematic approach including occurrence, fate and transport in various environmental matrices is needed to minimize uncertainties in risk assessment of chiral pharmaceuticals as emerging environmental contaminants.

Affiliation

Journal Details

This article was published in the following journal.

Name: Water research
ISSN: 1879-2448
Pages: 527-542

Links

DeepDyve research library

PubMed Articles [23869 Associated PubMed Articles listed on BioPortfolio]

Occurrence, elimination, enantiomeric distribution and intra-day variations of chiral pharmaceuticals in major wastewater treatment plants in Beijing, China.

The occurrence, eliminations, enantiomeric distribution and intra-day variations of five chiral pharmaceuticals (three beta-blockers and two antidepressants) were investigated in eight major WWTPs in ...

Advanced oxidation process-mediated removal of pharmaceuticals from water: A review.

Pharmaceuticals, which are frequently detected in natural and wastewater bodies as well as drinking water have attracted considerable attention, because they do not readily biodegrade and may persist ...

Aromatic organoarsenic compounds (AOCs) occurrence and remediation methods.

Many researchers at home and abroad have made a body of researches and have gained great achievements on the environmental occurrence, fate, and toxicity of inorganic arsenic. But there is less resear...

Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach.

An extensive use of pharmaceuticals and the widespread practices of their erroneous disposal measures have made these products contaminants of emerging concern (CEC). Especially, active pharmaceutical...

The fate and risk assessment of psychiatric pharmaceuticals from psychiatric hospital effluent.

Psychiatric pharmaceuticals are gaining public attention because of increasing reports of their occurrence in environment and their potential impact on ecosystems and human health. This work studied t...

Clinical Trials [3525 Associated Clinical Trials listed on BioPortfolio]

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose (MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with recurrent ova...

Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

This is a Phase I open-label dose escalation study of a single infusion of FATE-NK100 and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherap...

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: - Regimen A: FATE-NK1...

Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer

RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in th...

Characterization of the Metabolic Fate of an Oral Arginine Form

The purpose of this study is to compare the metabolic fate of two oral forms of L-Arginine in healthy subjects featuring metabolic syndrome related risk factors

Medical and Biotech [MESH] Definitions

Ecosystem and environmental activities, functions, or events.

Review of the medical necessity of hospital or other health facility admissions, upon or within a short time following an admission, and periodic review of services provided during the course of treatment.

Polymers of N-SUBSTITUTED GLYCINES containing chiral centers at the a-position of their side chains. These oligomers lack HYDROGEN BONDING donors, preventing formation of the usual intrachain hydrogen bonds but can form helices driven by the steric influence of chiral side chains.

Ecological and environmental entities, characteristics, properties, relationships and processes.

Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for Medicaid programs beginning in 1993.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article